The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC
The Prostate · 2026
DOI: 10.1002/pros.70213 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Prostate, 2026. Verfasst von Kohei Hashimoto und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, School of Medicine, Sapporo Medical University, Hokkaido, Sapporo, Japan. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Prostatic Neoplasms, Castration-Resistant, Prostate-Specific Antigen, Androstenes. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the Japanese Foundation for Multidisciplinary Cancer Treatment.
Abstract (Originalsprache)
Background
This study aimed to clarify whether variations in the lowest prostate‑specific antigen (PSA) level prior to the development of castration‑resistant prostate cancer (CRPC) influence the efficacy of subsequent enzalutamide (ENZ) or abiraterone plus prednisolone (ABI) therapy in metastatic CRPC.
Methods
Using data from the ENABLE study, an investigator‑initiated, multicenter, randomized controlled trial, patients were retrospectively categorized into two groups based on the lowest PSA level prior to metastatic CRPC development: ≤ 0.05 ng/mL (low group) and > 0.05 ng/mL (high group). Endpoints included time to PSA progression (TTPP), radiographic progression‑free survival (rPFS), docetaxel‑free survival (DFS), and overall survival (OS) in the overall study population and within the ABI and ENZ treatment arms.
Results
A total of 39 and 94 patients were classified into the low and high groups, respectively. In the overall population, survival outcomes did not differ significantly between the groups except for DFS (median 29.0 vs. 15.2 months, p = 0.0209). In the ABI arm (low group, n = 15; high group, n = 45), median TTPP, rPFS, DFS, and OS were undefined versus 4.7 months, 39.5 versus 9.8 months, 29.0 versus 14.0 months, and undefined versus 33.3 months in the low and high groups, respectively ( p = 0.0443, p = 0.0243 p = 0.0106, and p = 0.0319). In contrast, in the ENZ arm (low group, n = 24; high group, n = 49), no significant differences were observed in any endpoint between the two groups.
Conclusions
The findings of this study indicate that the lowest PSA level prior to CRPC onset may have a potential association with outcomes following subsequent ABI therapy, whereas no such trend was observed for ENZ in metastatic CRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, School of Medicine, Sapporo Medical University, Hokkaido, Sapporo, Japan.
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Ishikawa, Kanazawa, Japan.
- Department of Urology, Toyama Prefectural Central Hospital, Toyama, Japan.
- Department of Urology, Fukui-ken Saiseikai Hospital, Fukui, Japan.
- Department of Urology, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Asakita-ku, Japan.
- Department of Urology, Anjo Kosei Hospital, Anjo, Aichi, Japan.
ORCID-Profile: Kohei Hashimoto, Yuki Kato, Shuichi Tatarano, Nobumichi Tanaka, Noriyasu Kawai, Seiji Hoshi
Förderung
- the Japanese Foundation for Multidisciplinary Cancer Treatment
Zitieren
APA
Hashimoto, K., Izumi, K., Shima, T., Kato, Y., Mita, K., Okamura, T., Inoue, S., Tatarano, S., Tanaka, N., Kawai, N., Kamiyama, M., Chikazawa, I., Hoshi, S., Fukagai, T., Shigehara, K., Takahara, S., & Mizokami, A. (2026). The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC. The Prostate. https://doi.org/10.1002/pros.70213
Vancouver
Hashimoto K, Izumi K, Shima T, Kato Y, Mita K, Okamura T, et al. The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC. The Prostate. 2026. doi:10.1002/pros.70213
BibTeX
@article{Hashimoto2026,
author = {Hashimoto, Kohei and Izumi, Kouji and Shima, Takashi and Kato, Yuki and Mita, Koji and Okamura, Takehiko and Inoue, Shogo and Tatarano, Shuichi and Tanaka, Nobumichi and Kawai, Noriyasu and Kamiyama, Manabu and Chikazawa, Ippei and Hoshi, Seiji and Fukagai, Takashi and Shigehara, Kazuyoshi and Takahara, Shizuko and Mizokami, Atsushi},
title = {The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC},
journal = {The Prostate},
year = {2026},
doi = {10.1002/pros.70213}
}
EUVIMED